Johnson & Johnson is eager to report about its “COVID-19 vaccine”. Moreover, the company is confident that the upcoming vaccine will “meet the delivery target” for countries with which it has entered into “supply agreements”.
More and more officials from public heath sector are looking forward to “single-dose options” similar to what is being developed at Johnson & Johnson, whereby simplifying and boosting “inoculations” as vaccines from “Pfizer Inc and Moderna Inc” turn out to be complicated while its effects are “slower-than-hoped” and “require second shots weeks after the first”.
The 2021 profit forecast of the company goes way higher than “Wall Street estimates” which saw its share rise by “3.4% to $171.55”. However, the above mentioned outlook, informed the C.F.O, Joseph Wolk, does not take into consideration any potential contribution from COVID-19 vaccine. While, the price of the vaccine will be dependent upon the “number of doses secured by countries and organizations”. In Wolk’s words:
“We will let the science play out. Once we have the data, obtain regulatory authorization and finalize agreements to supply, we will provide financial updates as warranted”.
The company further informed that “its medical device unit” has seen continuous recovery even though there has been a recent surge in the number of COVID-19 patients. Nevertheless, the said division had been “hit hard earlier” as the pandemic brought down the number of cases involving “elective and non-urgent procedures” like “hip and knee replacement” for either hospitals were no choice but to “suspend such procedures” or “people avoided hospital care”.
Likewise, Q4 sales’ figures saw a marginal drop to “$6.59 billion”. While Reuters added:
“Adjusted profit of $1.86 per share beat estimates of $1.82 per share, helped by double-digit sales growth of Crohn’s disease drug Stelara and cancer treatment Darzalex”.
References:
reuters.com
More and more officials from public heath sector are looking forward to “single-dose options” similar to what is being developed at Johnson & Johnson, whereby simplifying and boosting “inoculations” as vaccines from “Pfizer Inc and Moderna Inc” turn out to be complicated while its effects are “slower-than-hoped” and “require second shots weeks after the first”.
The 2021 profit forecast of the company goes way higher than “Wall Street estimates” which saw its share rise by “3.4% to $171.55”. However, the above mentioned outlook, informed the C.F.O, Joseph Wolk, does not take into consideration any potential contribution from COVID-19 vaccine. While, the price of the vaccine will be dependent upon the “number of doses secured by countries and organizations”. In Wolk’s words:
“We will let the science play out. Once we have the data, obtain regulatory authorization and finalize agreements to supply, we will provide financial updates as warranted”.
The company further informed that “its medical device unit” has seen continuous recovery even though there has been a recent surge in the number of COVID-19 patients. Nevertheless, the said division had been “hit hard earlier” as the pandemic brought down the number of cases involving “elective and non-urgent procedures” like “hip and knee replacement” for either hospitals were no choice but to “suspend such procedures” or “people avoided hospital care”.
Likewise, Q4 sales’ figures saw a marginal drop to “$6.59 billion”. While Reuters added:
“Adjusted profit of $1.86 per share beat estimates of $1.82 per share, helped by double-digit sales growth of Crohn’s disease drug Stelara and cancer treatment Darzalex”.
References:
reuters.com
